Replimune Group Inc. (NASDAQ:REPL) changes shares on Friday trading session, with a change of -0.37% or -$0.08 shares. The trading starts at $21.60 and closed at $21.76 throughout the day. The trading session low price was $21.22 and day high was $22.00 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 0.16 million while its average volume is 149.12K. In other hand, the REPL market cap reached to $856.58M. While, its current target price is $21.68 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 5.24% and up 4.68% for month. Its quarterly performance was 141.69% above, while its half year performance is up 49.83%. REPL yearly performance stood at positive 64.62% and rise 51.08% for year-to-date. Current recommendation for Replimune Group Inc. is 1.70.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. REPL EPS (TTM) for 12-month is -1.52. EPS for this year is -15.60%, while for the next year its value is -2.21. Its EPS Q/Q reached -92.40%.
Let’s take a look on the analyst recommendations on REPL for the current month and previous month. For the current month, 8 of 8 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 8 analysts participate in stock recommendation. Out of 8, 0 rated it sell, 8 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $25.00-$40.00. Average target price for REPL was reached at $29.38.
Omega Fund Management (US) Inc., Redmile Group, LLC and Bain Capital Life Sciences Investors, LLC are the top three holders in Replimune Group Inc. (REPL) stock. On Mar 30, 2020, Omega Fund Management (US) Inc. has 5.32 million shares which valued 53.07 million. On Mar 30, 2020, Redmile Group, LLC owned 2.98 million shares which valued at 29.72 million. On Mar 30, 2020, Bain Capital Life Sciences Investors, LLC has a total of 2.84 million shares which valued at 28.3 million. In the end, Bain Capital Life Sciences Investors, LLC have 7.72% shares outstanding of Replimune Group Inc. (REPL) on Mar 30, 2020. The insider ownership moved to 6.30% and institutional holding shifted to 88.30%.
The company posted an EPS (TTM) of -1.52. According to the most recent quarter report on (Jun 2020), 6 analysts estimated an average EPS of -0.46, while -0.3 EPS posted a year ago period. Analyst Estimated EPS for REPL published in the report was -0.51–0.41 during the same period. Comparing with last year, the average estimated EPS was -0.3 which is higher than -0.41 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for REPL rise 43.55% for period of 200 days. SMA for 50 days was 23.73% which is showing green signal, while SMA-20 was 4.14%. The moving average value for Replimune Group Inc. (REPL) is 15.70 and 20.03 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in REPL stock. On Feb 20, Coffin Robert, Pres & Chief Res & Dev Officer, sold 24,250 trading shares at the cost of $17.04, which valued at 0.41 million. On Feb 12, Coffin Robert, Pres & Chief Res & Dev Officer, sold 48,500 shares at the cost of $17.04, with total shares of 2,218,118. On Nov 18, Rhodes Jason P, Director, bought 1,100,000 shares at the cost of 13.61. After this transaction, Rhodes Jason P total shares reached to 1,100,000 which valued at 14.97 million.